Profusa 3Q 2026: EPS ($6.23) — 10-Q Summary

Profusa reported no revenue in Q3 2026, with net loss narrowing 81% YoY to $4.95M, and EPS at ($6.23). Expenses fell due to workforce reduction and lower costs. The company received ISO 13485:2016 certification for its Lumee Oxygen Platform.

Original reporting
Published Nov 13, 2026, 9:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Profusa 3Q 2026: EPS ($6.23) — 10-Q Summary — source image
Decision brief

The 30-second read

$PFSANeutralLow
01

Why it matters

The 10‑Q provides the first detailed expense breakdown and workforce reduction, offering insight into the company's path to profitability.

02

Market read

While the filing is material for PFSA shareholders, its scale limits broader market relevance.

03

What to watch

No revenue yet; reliance on future regulatory approvals and market adoption.

Relevance 6/10Novelty 6/10Timing: after‑hours filing

Background

Profusa is a micro‑cap med‑tech company developing oxygen‑delivery platforms, previously reporting larger losses.

Company-level read

Ticker impact

$PFSANeutralHigh confidence
Context

Profusa filed its 10‑Q reporting a net loss of $4.95 M and EPS of -$6.23, a material update that narrows loss 81% YoY.

Expected impact

modest downside pressure as investors weigh continued loss against expense reductions

Evidence & confidence

Losses remain large; market may react negatively despite improvement, especially given low revenue.

Market effects

Highlights cost‑cutting trends in the med‑tech diagnostics space.

Limited to US micro‑cap investors.

Minimal broader market impact.

Counterpoint

The loss narrowing could signal a turnaround if expense discipline continues.

Key entities

  • Profusa, Inc.

    US‑listed med‑tech firm (ticker PFSA).

Related articles

$PFSALow

Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company

Profusa, Inc. (PFSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of w

$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

$PFSAMedAI 8/10

PFSA Stock Falls 19% Amid Diagnostics Acquisition News

Profusa (PFSA) said it signed a non-binding term sheet to acquire a privately held commercial diagnostics and toxicology testing company. The target estimates 2025 net revenues of about $111 million. Profusa would issue shares equal to 19.99% plus non-voting convertible preferred stock, subject to approval, and expects about $7 million financing via convertible notes. PFSA shares fell sharply after the news.